CONMED Statistics
Total Valuation
CONMED has a market cap or net worth of $2.12 billion. The enterprise value is $3.02 billion.
| Market Cap | 2.12B |
| Enterprise Value | 3.02B |
Important Dates
The next estimated earnings date is Wednesday, January 29, 2025, after market close.
| Earnings Date | Jan 29, 2025 |
| Ex-Dividend Date | Sep 16, 2024 |
Share Statistics
CONMED has 30.89 million shares outstanding. The number of shares has decreased by -0.18% in one year.
| Current Share Class | 30.89M |
| Shares Outstanding | 30.89M |
| Shares Change (YoY) | -0.18% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.86% |
| Owned by Institutions (%) | 111.69% |
| Float | 30.61M |
Valuation Ratios
The trailing PE ratio is 16.26 and the forward PE ratio is 14.76. CONMED's PEG ratio is 0.97.
| PE Ratio | 16.26 |
| Forward PE | 14.76 |
| PS Ratio | 1.64 |
| Forward PS | 1.53 |
| PB Ratio | 2.27 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 12.76 |
| P/OCF Ratio | 11.78 |
| PEG Ratio | 0.97 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.88, with an EV/FCF ratio of 18.19.
| EV / Earnings | 22.94 |
| EV / Sales | 2.35 |
| EV / EBITDA | 13.88 |
| EV / EBIT | 20.47 |
| EV / FCF | 18.19 |
Financial Position
The company has a current ratio of 2.27, with a Debt / Equity ratio of 1.01.
| Current Ratio | 2.27 |
| Quick Ratio | 0.96 |
| Debt / Equity | 1.01 |
| Debt / EBITDA | 4.16 |
| Debt / FCF | 5.66 |
| Interest Coverage | 3.89 |
Financial Efficiency
Return on equity (ROE) is 15.24% and return on invested capital (ROIC) is 5.01%.
| Return on Equity (ROE) | 15.24% |
| Return on Assets (ROA) | 3.98% |
| Return on Capital (ROIC) | 5.01% |
| Revenue Per Employee | $322,029 |
| Profits Per Employee | $32,935 |
| Employee Count | 4,000 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.70 |
Taxes
In the past 12 months, CONMED has paid $28.33 million in taxes.
| Income Tax | 28.33M |
| Effective Tax Rate | 17.70% |
Stock Price Statistics
The stock price has decreased by -37.91% in the last 52 weeks. The beta is 1.47, so CONMED's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | -37.91% |
| 50-Day Moving Average | 70.39 |
| 200-Day Moving Average | 71.72 |
| Relative Strength Index (RSI) | 39.57 |
| Average Volume (20 Days) | 426,869 |
Short Selling Information
The latest short interest is 846,967, so 2.74% of the outstanding shares have been sold short.
| Short Interest | 846,967 |
| Short Previous Month | 1.02M |
| Short % of Shares Out | 2.74% |
| Short % of Float | 2.77% |
| Short Ratio (days to cover) | 5.21 |
Income Statement
In the last 12 months, CONMED had revenue of $1.29 billion and earned $131.74 million in profits. Earnings per share was $4.22.
| Revenue | 1.29B |
| Gross Profit | 718.96M |
| Operating Income | 147.65M |
| Pretax Income | 123.90M |
| Net Income | 131.74M |
| EBITDA | 217.80M |
| EBIT | 147.65M |
| Earnings Per Share (EPS) | $4.22 |
Balance Sheet
The company has $38.47 million in cash and $940.81 million in debt, giving a net cash position of -$902.34 million or -$29.21 per share.
| Cash & Cash Equivalents | 38.47M |
| Total Debt | 940.81M |
| Net Cash | -902.34M |
| Net Cash Per Share | -$29.21 |
| Equity (Book Value) | 932.90M |
| Book Value Per Share | 30.21 |
| Working Capital | 358.69M |
Cash Flow
In the last 12 months, operating cash flow was $180.03 million and capital expenditures -$13.90 million, giving a free cash flow of $166.13 million.
| Operating Cash Flow | 180.03M |
| Capital Expenditures | -13.90M |
| Free Cash Flow | 166.13M |
| FCF Per Share | $5.38 |
Margins
Gross margin is 55.82%, with operating and profit margins of 11.46% and 10.23%.
| Gross Margin | 55.82% |
| Operating Margin | 11.46% |
| Pretax Margin | 12.43% |
| Profit Margin | 10.23% |
| EBITDA Margin | 16.91% |
| EBIT Margin | 11.46% |
| FCF Margin | 12.90% |
Dividends & Yields
This stock pays an annual dividend of $0.80, which amounts to a dividend yield of 1.17%.
| Dividend Per Share | $0.80 |
| Dividend Yield | 1.17% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 18.95% |
| Buyback Yield | 0.18% |
| Shareholder Yield | 1.35% |
| Earnings Yield | 6.21% |
| FCF Yield | 7.84% |
Analyst Forecast
The average price target for CONMED is $82.83, which is 20.69% higher than the current price. The consensus rating is "Buy".
| Price Target | $82.83 |
| Price Target Difference | 20.69% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 6.88% |
| EPS Growth Forecast (5Y) | 30.38% |
Stock Splits
The last stock split was on September 10, 2001. It was a forward split with a ratio of 1.5:1.
| Last Split Date | Sep 10, 2001 |
| Split Type | Forward |
| Split Ratio | 1.5:1 |
Scores
CONMED has an Altman Z-Score of 2.4 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.4 |
| Piotroski F-Score | 8 |